Arkolith/Insider Trading/RXRX/Form 4

Gibson Christopher

DirectorRECURSION PHARMACEUTICALS, INC. (RXRX) · full profile →Form 4 · filed Feb 6, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$165K
Net Open-Market Flow
-$165K
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 6, 2026Grant(A)30K—$0944K
Feb 6, 2026Tax withholding(F)10K$3.56$37K934K
Feb 4, 2026Sell(S)40K$4.12$165K914K
Feb 4, 2026Conversion(C)40K—$0954K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 4, 2026Conversion(C)40K—$04.6M

Transaction Codes

A
Grant / award
F
Shares withheld for taxes
S
Open-market sale
C
Conversion of a derivative

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001601830-26-000008) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML